MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

A Study to Evaluate the Efficacy and Safety of Intravenous Prasinezumab in Participants With Early Parkinson’s Disease (PADOVA): Rationale, Design, and Baseline Data

T. Nikolcheva, G. Pagano, N. Pross, T. Simuni, K. Marek, R. Postuma, N. Pavese, F. Stocchi, K. Seppi, A. Monnet, N. Shariati, L. Rutten-Jacobs, S. Zanigni, T. Kustermann, K. Taylor, D. Trundell, H. Svoboda, A. Bonni, P. Fontoura, R. Doody (BASEL, Switzerland)

Meeting: 2023 International Congress

Abstract Number: 101

Keywords: Alpha-synuclein, Dopaminergic neurons, Parkinson’s

Category: Parkinson’s Disease: Clinical Trials

Objective: The study will evaluate the efficacy and safety of prasinezumab in individuals with early-stage Parkinson’s disease (PD) on stable symptomatic therapy.

Background: Available treatments for PD do not slow clinical progression. Alpha synuclein is a key driver of PD pathology. Prasinezumab is a humanized monoclonal antibody that binds to aggregated alpha-synuclein. Results from a previous phase 2 study showed that prasinezumab reduced 1-year motor progression measured by MDS-UPDRS part III compared to placebo in individuals with early-stage PD (PASADENA).

Method: The PADOVA study is a randomized, double-blind, placebo-controlled multicenter study. Individuals with early PD, recruited across North America and Europe, will receive monthly intravenous doses of prasinezumab 1,500 mg or placebo for at least 76 weeks, followed by a 2-year extension in which all participants receive active treatment. Key inclusion criteria are: aged 50-85 years; Diagnosis of idiopathic PD based on MDS criteria; Hoehn & Yahr (H&Y) Stage I or II; time from diagnosis 3 months to 3 years; DAT-SPECT imaging consistent with PD; and on a stable dose of monoamine oxidase B (MAO-B) inhibitor or levodopa. Study design assumptions for sample size and study duration were built using a patient cohort from the Parkinson’s Progression Marker Initiative (PPMI) and PASADENA. We report baseline characteristics for the MAO-B inhibitor- and levodopa-treated PADOVA cohorts and compare the PADOVA, PASADENA and PPMI populations.

Results: Baseline demographic characteristics, motor and non-motor symptoms (assessed using MDS-UPDRS) will be presented.

Conclusion: The PADOVA study population is suitable for investigating the potential of prasinezumab to slow disease progression in individuals with early PD on stable symptomatic therapy. Trial Registration: NCT04777331.

To cite this abstract in AMA style:

T. Nikolcheva, G. Pagano, N. Pross, T. Simuni, K. Marek, R. Postuma, N. Pavese, F. Stocchi, K. Seppi, A. Monnet, N. Shariati, L. Rutten-Jacobs, S. Zanigni, T. Kustermann, K. Taylor, D. Trundell, H. Svoboda, A. Bonni, P. Fontoura, R. Doody. A Study to Evaluate the Efficacy and Safety of Intravenous Prasinezumab in Participants With Early Parkinson’s Disease (PADOVA): Rationale, Design, and Baseline Data [abstract]. Mov Disord. 2023; 38 (suppl 1). https://www.mdsabstracts.org/abstract/a-study-to-evaluate-the-efficacy-and-safety-of-intravenous-prasinezumab-in-participants-with-early-parkinsons-disease-padova-rationale-design-and-baseline-data/. Accessed May 21, 2025.
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2023 International Congress

MDS Abstracts - https://www.mdsabstracts.org/abstract/a-study-to-evaluate-the-efficacy-and-safety-of-intravenous-prasinezumab-in-participants-with-early-parkinsons-disease-padova-rationale-design-and-baseline-data/

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • An Apparent Cluster of Parkinson's Disease (PD) in a Golf Community
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • The hardest symptoms that bother patients with Parkinson's disease
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Patients with Essential Tremor Live Longer than their Relatives
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Welcome to the MDS Abstracts Site
  • An Apparent Cluster of Parkinson's Disease (PD) in a Golf Community
  • The hardest symptoms that bother patients with Parkinson's disease
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Patients with Essential Tremor Live Longer than their Relatives
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley